Stokes Family Office LLC Has $8.50 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Stokes Family Office LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% in the 4th quarter, HoldingsChannel reports. The fund owned 58,739 shares of the company’s stock after selling 896 shares during the period. Johnson & Johnson comprises approximately 0.9% of Stokes Family Office LLC’s holdings, making the stock its 24th biggest position. Stokes Family Office LLC’s holdings in Johnson & Johnson were worth $8,495,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Swedbank AB boosted its stake in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after purchasing an additional 329,473 shares during the last quarter. United Bank boosted its stake in shares of Johnson & Johnson by 5.6% in the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after purchasing an additional 202 shares during the last quarter. MidAtlantic Capital Management Inc. bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $56,000. Finally, OneAscent Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $203,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $164.24 on Wednesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a 50-day simple moving average of $155.73 and a 200 day simple moving average of $156.25. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market capitalization of $395.80 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.29 earnings per share. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on JNJ shares. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Raymond James cut their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.